

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

Phospho-Axl (Tyr702) (D12B2) Rabbit mAb

RRID:AB_10544794

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5724, RRID:AB_10544794

Antibody Information

URL: http://antibodyregistry.org/AB_10544794

Proper Citation: Cell Signaling Technology Cat# 5724, RRID:AB_10544794

Target Antigen: Phospho-Axl (Tyr702) (D12B2) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10544794, AB_10548763.

Antibody Name: Phospho-Axl (Tyr702) (D12B2) Rabbit mAb

Description: This monoclonal targets Phospho-Axl (Tyr702) (D12B2) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_10544794

Vendor: Cell Signaling Technology

Catalog Number: 5724

Record Creation Time: 20250820T045827+0000

Record Last Update: 20250820T202611+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Axl (Tyr702) (D12B2) Rabbit mAb.

No alerts have been found for Phospho-Axl (Tyr702) (D12B2) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pirson S, et al. (2025) AXL promotes lymphangiogenesis by amplifying VEGF-C-mediated AKT pathway. Cellular and molecular life sciences : CMLS, 82(1), 95.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell chemical biology, 32(6), 839.

Danielli SG, et al. (2024) Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics, 23(6), 864.

Ko A, et al. (2023) LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL. Cancer discovery, 13(3), 702.

Hagege A, et al. (2022) Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell reports. Medicine, 3(9), 100659.

Shen JZ, et al. (2022) A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. Molecular cell, 82(6), 1123.

Synn CB, et al. (2022) SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. Clinical & translational immunology, 11(1), e1364.

Cooke M, et al. (2021) FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma. Cell reports, 37(5), 109905.

Hoj JP, et al. (2019) A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. Cell reports, 29(11), 3421.